Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Grainger

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
The Patient|July 19, 2012
A pilot study to identify areas for further improvements in patient and public involvement in health technology assessments for medicinesJosie Messina, David L Grainger
International Journal of Technology Assessment in Health Care|January 12, 2010
Coverage with Evidence Development: applications and issuesPaul Trueman, David L Grainger, Kristen E Downs
Schizophrenia Bulletin|June 11, 2003
Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophreniaJosephine Mauskopf, Matthew Muroff, P Joseph Gibson, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
The Patient|July 19, 2012
A pilot study to identify areas for further improvements in patient and public involvement in health technology assessments for medicinesJosie Messina, David L Grainger
International Journal of Technology Assessment in Health Care|January 12, 2010
Coverage with Evidence Development: applications and issuesPaul Trueman, David L Grainger, Kristen E Downs
Schizophrenia Bulletin|June 11, 2003
Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophreniaJosephine Mauskopf, Matthew Muroff, P Joseph Gibson, et al.
Pageof 1